The current pandemic outbreak of corona virus SARS-CoV-2 shows the need for comprehensive European cooperation in drug development and the importance of genetic material and sequence data in research concerning this unknown disease. As corona virus SARS-CoV-2 is spreading across Europe and worldwide, national authorities and the European Union (EU) institutions do their utmost to address the pandemic and accelerate innovation to protect global health. In order to be prepared and to be able to respond immediately to serious epidemic and pandemic diseases, the EU has already adopted the Decision No (EU) 1082/2013 on serious cross-border threats to health. The World Health Organization (WHO) has established a global system to collect genetic material and information to protect a global influenza pandemic outbreak. The article describes the current legal landscape under EU and international law.

当前的冠状病毒SARS -CoV-2大流行暴发表明，需要在药物开发方面进行全面的欧洲合作，并且在有关这种未知疾病的研究中，遗传物质和序列数据的重要性。随着冠状病毒SARS -CoV-2在欧洲和世界范围内传播，各国主管部门和欧盟（EU）机构将尽最大努力应对这一大流行并加速创新以保护全球健康。为了做好准备并能够立即对严重的流行病和大流行疾病做出反应，欧盟已经通过了关于严重跨界健康威胁的第1082/2013号决定。世界卫生组织（WHO）建立了一个全球系统来收集遗传物质和信息，以保护全球流感大流行的爆发。本文介绍了欧盟和国际法下的当前法律前景。